My inbox at work has been receiving promotions for the new American Chemical Society journal ACS Chemical Biology. I've looked it over, and it's the sort of thing that I like to read. I should also note that they've started a wiki on the whole topic of just what chemical biology is, and it'll be interesting to see if they get contributions.
But there are other e-mails demanding my attention. The Nature Publishing Group has been sending me notices about new journal, Nature Chemical Biology. That one's not bad, either. Watching them fight with the ACS journal over the exact same papers should be fun.
Of course, you wouldn't expect a powerhouse like Elsevier to stay out of this, but they can point out that they were already there: Chemistry and Biology has been around for years. I don't read it as often as I probably should, but it's published some interesting articles.
And if Elsevier is there, can Wiley be far behind? That would be the Euro-flavored ChemBioChem, awkwardly named but a pretty good read. They have a bit more of a drug-discovery angle to them than the Elsevier journal, to my eye, and they've also been around a few years.
That angle is supposedly going to be dealt with more explicitly by Chemical Biology and Drug Design. This is the journal formerly known as the Journal of Peptide Research, but the times, they have changed. Would you be interested in BioMedCentral's BMC Chemical Biology? If you have some time after that, the Royal Society of Chemistry has synthesized their Chemical Biology Virtual Journal by amalgamating relevant papers from their other publications. How about Current Opinion in Chemical Biology, in case you're having trouble getting a handle on what's going on?
What's going on, as is probably clear by now, is a major publishing pileup. But there's something to be learned from it. If the various publishers didn't think that there was a market (for submissions and for subscriptions) they wouldn't be so eager to get in on the action. In some coming posts, I'll be taking a look at just what action that is, and whether it represents a takeover of biology by chemistry or the reverse.